Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Micko, ASG; Wöhrer, A; Höftberger, R; Vila, G; Marosi, C; Knosp, E; Wolfsberger, S.
MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Pituitary. 2017; 20(6):643-653
Doi: 10.1007/s11102-017-0829-3
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Wolfsberger Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: Knowledge of biological behavior is crucial for clinical management of functioning pituitary macroadenomas. For recurrent cases unresponsive to standard treatment, temozolomide (TMZ) has been used as a therapeutic alternative. MGMT (O6-methyl-guanine-DNA methyltransferase) and MSH6 (mutS homolog 6) immunoexpression have been linked to the response to TMZ treatment and MGMT immunoexpression has been additionally linked to early recurrence of non-functioning pituitary adenomas. The aim of this study was to assess the prognostic value of MGMT and MSH6 immunoexpression for aggressive functioning pituitary adenomas. METHODS: The study cohort comprised a single center series of 76 patients who underwent an operation for functioning pituitary macroadenoma. We retrospectively compared 38 patients with postoperative persistent or recurrent disease with another set of 38 patients who were in endocrine remission. RESULTS: Low-to-moderate MGMT immunoexpression (<50%) was significantly more frequent in the group with persistent/recurrent disease than in cases of endocrine remission (66 vs. 21%, p < 0.001). Furthermore, adenomas with low-to-moderate MGMT immunoexpression were significantly more often recurrent (76 vs. 30%, p < 0.001) and invasive (64 vs. 28%, p = 0.002). CONCLUSION: In our series, low-to-moderate MGMT immunoexpression was the only marker that significantly correlated with surgical invasiveness and recurrence in functioning pituitary macroadenomas. Therefore, in the future, MGMT status may be considered an additional marker for understanding the biological behavior of pituitary adenomas.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Antineoplastic Agents, Alkylating - therapeutic use
- DNA Modification Methylases - metabolism
- DNA Repair Enzymes - metabolism
- DNA-Binding Proteins - metabolism
- Dacarbazine - analogs & derivatives, therapeutic use
- Female - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Neoplasm Recurrence, Local - drug therapy, immunology, metabolism
- O(6)-Methylguanine-DNA Methyltransferase - metabolism
- Pituitary Neoplasms - drug therapy, immunology, metabolism
- Retrospective Studies - administration & dosage
- Temozolomide - administration & dosage
- Tumor Suppressor Proteins - metabolism
- Find related publications in this database (Keywords)
- Aggressive pituitary adenoma
- MGMT
- MSH6
- TMZ